Bruce Downey
CIK 1237257 · Chairman & CEO · last filed 2024-06-21
Bruce Downey is a Chairman & CEO who has filed 46 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for CCCC, was dated Jun 21, 2024. Across all open-market trades the lifetime net is −$188.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $16.0M across reported positions. 20 SEC filings were submitted jointly with CARDINAL HEALTH INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MNTA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CCCC | Director | 489,542 | $3.02 | $1.48M | $0 | 6 | 2024-06-21 |
| CAH | Director | 53,929 | $269.35 | $14.53M | $0 | 16 | 2022-11-10 |
| MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Director | 0 | — | — | -$188.6K | 15 | 2020-10-01 |
| MELINTA THERAPEUTICS, INC. /NEW/ (MLNT) Delisted | Director | — | — | — | $0 | 2 | 2019-06-12 |
| BARR PHARMACEUTICALS INC (BRL) Delisted | Chairman & CEO | — | — | — | $0 | 4 | 2008-11-24 |
Recent Filings
46 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-21 | CCCC | Grant (A) | — | $0 | EDGAR |
| 2023-12-20 | CAH | Notice (144) | −8,411 | -$835.5K | EDGAR |
| 2023-12-04 | CAH | Notice (144) | −24,890 | -$2.66M | EDGAR |
| 2023-06-16 | CCCC | Grant (A) | — | $0 | EDGAR |
| 2022-11-10 | CAH | Grant (A) | +2,308 | $0 | EDGAR |
| 2022-06-23 | CCCC | Grant (A) | — | $0 | EDGAR |
| 2021-11-15 | CAH | Grant (A) | +3,709 | $0 | EDGAR |
| 2021-06-17 | CCCC | Grant (A) | — | $0 | EDGAR |
| 2020-11-10 | CAH | Grant (A) | +3,339 | $0 | EDGAR |
| 2020-10-06 | CCCC | Conv (C) | +489,542 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.